Hi Wolf, excellent post.
I thought you covered a lot of the key points and I share your views. Like you I was disappointed with the EU delays and believe a simple phone call early on into the process could have avoided this long a delay. Easy to say what should be done after the fact, I guess.
Two months is not the end of the world, but I am a very frustrated Dimethaid investor with all the delays we have experienced with HPB and FDA aprovals. These should have (and we were led to believe) they would have happened long ago. This is just another straw that is wearing on this camel's back.
Like others I think the next 6 months will be make or break for Dimethaid and Rebecca. If she is unable to deliver the goods like she promised in the AGM, two years ago (if I remember correctly), then she needs to consider stepping aside. That said I am hopeful(praying) that the entire team will come through.
I liked the news about the OXO purchase, sketchy as it was, I think she outlined her strategy for all to see and I appreciate that. I always believed that it made too much sense not to and they have such a strong relationship with OXo that it is an excellent fit. This is proper way to do an acquisition; when you intimating understand the products and the people as opposed to some acquisitions that I have seen where management figures out what they purcahsed AFTER they paid for it (e.g., Laidlaw, GEac).
Like you I am basing a lot of my optimism on the excellent Vanderbelt phase II results and confirmation from the safety board to continue the phase III in the face of adverse events. I think OXo is a great purchase and would expect that after the results are announced, Rebecca will list on NASDAQ and try to raise some serious money (US$50 - 75 million). We shall see.
In any event, I expect all the fireworks to begin in September and expect little in the way of meaniful news before that.
John |
